NO20006023L - Celleadhesjonsinhibitor samt farmasöytiske sammensetninger inneholdende denne - Google Patents

Celleadhesjonsinhibitor samt farmasöytiske sammensetninger inneholdende denne

Info

Publication number: NO20006023L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; cell adhesion; well; compositions containing; adhesion inhibitor
Prior art date: 1998-05-28

Application number

NO20006023A

Other languages

English (en)

Other versions

NO317990B1 (no

NO20006023D0 (no

Inventor

Wen-Cherng Lee

Alan Gill

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-28

Filing date

2000-11-28

Publication date

2001-01-17

2000-11-28 Application filed by Biogen Inc filed Critical Biogen Inc

2000-11-28 Publication of NO20006023D0 publication Critical patent/NO20006023D0/no

2001-01-17 Publication of NO20006023L publication Critical patent/NO20006023L/no

2005-01-17 Publication of NO317990B1 publication Critical patent/NO317990B1/no

Links

230000021164 cell adhesion Effects 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
-1 2-methylphenylamino Chemical group 0.000 abstract 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
229940000635 beta-alanine Drugs 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20006023A 1998-05-28 2000-11-28 Celleadhesjonsinhibitor samt farmasoytiske sammensetninger inneholdende denne NO317990B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8706498P	1998-05-28	1998-05-28
PCT/US1999/011924 WO1999061421A1 (en)	1998-05-28	1999-05-28	A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (3)

Publication Number	Publication Date
NO20006023D0 NO20006023D0 (no)	2000-11-28
NO20006023L true NO20006023L (no)	2001-01-17
NO317990B1 NO317990B1 (no)	2005-01-17

Family

ID=22202907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006023A NO317990B1 (no)	1998-05-28	2000-11-28	Celleadhesjonsinhibitor samt farmasoytiske sammensetninger inneholdende denne

Country Status (31)

Country	Link
US (1)	US6495525B1 (no)
EP (1)	EP1082302B1 (no)
JP (1)	JP2002516309A (no)
KR (1)	KR100636713B1 (no)
CN (1)	CN1148350C (no)
AT (1)	ATE256659T1 (no)
AU (1)	AU764108B2 (no)
BG (1)	BG65021B1 (no)
CA (1)	CA2333656C (no)
CZ (1)	CZ298413B6 (no)
DE (1)	DE69913687T2 (no)
DK (1)	DK1082302T3 (no)
EA (1)	EA002988B1 (no)
EE (1)	EE04639B1 (no)
ES (1)	ES2211096T3 (no)
HK (1)	HK1035726A1 (no)
HU (1)	HUP0102255A3 (no)
IL (1)	IL139967A (no)
IS (1)	IS5737A (no)
MX (1)	MXPA00011774A (no)
NO (1)	NO317990B1 (no)
NZ (1)	NZ509199A (no)
PL (1)	PL198189B1 (no)
PT (1)	PT1082302E (no)
SI (1)	SI1082302T1 (no)
SK (1)	SK285280B6 (no)
TR (1)	TR200100190T2 (no)
UA (1)	UA65623C2 (no)
WO (1)	WO1999061421A1 (no)
YU (1)	YU75500A (no)
ZA (1)	ZA200007300B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69824037T2 (de) *	1997-11-24	2005-06-02	Merck & Co., Inc.	Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6645939B1 (en)	1997-11-24	2003-11-11	Merck & Co., Inc.	Substituted β-alanine derivatives as cell adhesion inhibitors
US7618630B2 (en)	1998-09-14	2009-11-17	Board Of Regents, The University Of Texas System	Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP1113810B1 (en) *	1998-09-14	2008-12-31	Board of Regents, The University of Texas System	Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
US6525069B1 (en)	1998-12-18	2003-02-25	Bristol-Myers Squibb Pharma Co.	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6630503B1 (en)	1999-08-13	2003-10-07	Biogen, Inc.	Cell adhesion inhibitors
CZ20022072A3 (cs)	1999-12-28	2003-05-14	Pfizer Products Inc.	Nepeptidylové inhibitory VLA-4 dependentní buněčné vazby použitelné pro léčbu zánětlivých, autoimunitních a respiračních onemocnění
ATE524441T1 (de)	2000-12-28	2011-09-15	Daiichi Seiyaku Co	Vla-4-inhibitoren
CN1826336B (zh)	2003-07-24	2010-06-02	第一制药株式会社	环己烷羧酸类
US7419666B1 (en)	2004-02-23	2008-09-02	Massachusetts Eye And Ear Infirmary	Treatment of ocular disorders
US7196112B2 (en)	2004-07-16	2007-03-27	Biogen Idec Ma Inc.	Cell adhesion inhibitors
GT200500321A (es) *	2004-11-09	2006-09-04		Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) *	2006-03-08	2010-03-23	Microsoft Corporation	Multi-cache cooperation for response output caching
RU2009107030A (ru) *	2006-08-02	2010-09-10	Джензим Корпорейшн (Us)	Комбинированная терапия
EP2510941A3 (en)	2007-02-20	2013-01-23	Merrimack Pharmaceuticals, Inc.	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2009234253C1 (en)	2008-04-11	2015-05-07	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
CN102282168A (zh)	2008-11-18	2011-12-14	梅里麦克制药股份有限公司	人血清白蛋白接头以及其结合物
DK2558499T3 (en)	2010-04-16	2017-07-24	Biogen Ma Inc	Anti-VLA-4 antibodies
US20150202287A1 (en)	2012-08-30	2015-07-23	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
CN112867394B (zh)	2018-06-04	2024-09-13	马萨诸塞州渤健公司	具有降低的效应功能的抗vla-4抗体
CN112969700B (zh)	2018-10-30	2024-08-20	吉利德科学公司	作为α4β7整合素抑制剂的咪唑并吡啶衍生物
EP3873605B1 (en)	2018-10-30	2024-10-23	Gilead Sciences, Inc.	Compounds for inhibition of alpha4beta7 integrin
KR20240015737A (ko)	2018-10-30	2024-02-05	길리애드 사이언시즈, 인코포레이티드	알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en)	2018-10-30	2023-07-13	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
CA3148613A1 (en)	2019-08-14	2021-02-18	Gilead Sciences, Inc.	Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1149971B (it)	1979-06-11	1986-12-10	Syntex Inc	Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en)	1985-01-23	1988-02-16	Abbott Laboratories	Functionalized peptidylaminoalcohols
US4826815A (en)	1985-05-17	1989-05-02	Abbott Laboratories	Renin inhibiting compounds
DK163689A (da)	1988-04-08	1989-10-30	Sandoz Ag	Peptidderivater
ATE131471T1 (de)	1989-12-22	1995-12-15	Commw Scient Ind Res Org	An fette gebundene aminosäuren, peptide oder deren derivate
CA2043741C (en)	1990-06-07	2003-04-01	Kiyofumi Ishikawa	Endothelin antagonistic peptide derivatives
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
US5260277A (en) *	1990-09-10	1993-11-09	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en)	1990-11-15	1992-05-29	Tanabe Seiyaku Co. Ltd.	Substituted urea and related cell adhesion modulation compounds
EP0519748B1 (en)	1991-06-21	1998-09-02	Merck & Co. Inc.	Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
EP0617705B1 (en)	1991-11-22	1997-09-24	Yeda Research And Development Company, Ltd.	Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
WO1993012809A1 (en)	1991-12-24	1993-07-08	Fred Hutchinson Cancer Research Center	Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de)	1992-04-13	1993-10-14	Cassella Ag	Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en)	1992-07-26	1996-05-14	Yeda Res & Dev	Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
SG52262A1 (en)	1993-01-08	1998-09-28	Tanabe Seiyaku Co	Peptide inhibitors of cell adhesion
US5314902A (en)	1993-01-27	1994-05-24	Monsanto Company	Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de)	1993-03-26	1994-09-29	Cassella Ag	Neue Harnstoffderivate, ihre Herstellung und Verwendung
CA2159192C (en)	1993-04-09	2006-07-25	Keiichi Tanaka	Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5770573A (en)	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en)	1994-03-07	1995-07-18	Warner-Lambert Company	1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) *	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
WO1998004247A1 (en) *	1996-07-25	1998-02-05	Biogen, Inc.	Cell adhesion inhibitors

1999
- 1999-05-28 CN CNB998080020A patent/CN1148350C/zh not_active Expired - Fee Related
- 1999-05-28 AT AT99926019T patent/ATE256659T1/de not_active IP Right Cessation
- 1999-05-28 EE EEP200000698A patent/EE04639B1/xx not_active IP Right Cessation
- 1999-05-28 AU AU42192/99A patent/AU764108B2/en not_active Ceased
- 1999-05-28 CZ CZ20004425A patent/CZ298413B6/cs not_active IP Right Cessation
- 1999-05-28 EA EA200001236A patent/EA002988B1/ru not_active IP Right Cessation
- 1999-05-28 JP JP2000550827A patent/JP2002516309A/ja active Pending
- 1999-05-28 SK SK1810-2000A patent/SK285280B6/sk not_active IP Right Cessation
- 1999-05-28 UA UA2000127603A patent/UA65623C2/uk unknown
- 1999-05-28 DE DE69913687T patent/DE69913687T2/de not_active Expired - Fee Related
- 1999-05-28 WO PCT/US1999/011924 patent/WO1999061421A1/en active IP Right Grant
- 1999-05-28 NZ NZ509199A patent/NZ509199A/en unknown
- 1999-05-28 CA CA002333656A patent/CA2333656C/en not_active Expired - Fee Related
- 1999-05-28 PT PT99926019T patent/PT1082302E/pt unknown
- 1999-05-28 PL PL344440A patent/PL198189B1/pl not_active IP Right Cessation
- 1999-05-28 SI SI9930526T patent/SI1082302T1/xx unknown
- 1999-05-28 ES ES99926019T patent/ES2211096T3/es not_active Expired - Lifetime
- 1999-05-28 TR TR2001/00190T patent/TR200100190T2/xx unknown
- 1999-05-28 EP EP99926019A patent/EP1082302B1/en not_active Expired - Lifetime
- 1999-05-28 IL IL13996799A patent/IL139967A/xx not_active IP Right Cessation
- 1999-05-28 DK DK99926019T patent/DK1082302T3/da active
- 1999-05-28 KR KR1020007013421A patent/KR100636713B1/ko not_active IP Right Cessation
- 1999-05-28 HU HU0102255A patent/HUP0102255A3/hu unknown
- 1999-05-28 YU YU75500A patent/YU75500A/sh unknown
- 1999-05-28 MX MXPA00011774A patent/MXPA00011774A/es not_active IP Right Cessation
2000
- 2000-11-28 US US09/724,107 patent/US6495525B1/en not_active Expired - Fee Related
- 2000-11-28 NO NO20006023A patent/NO317990B1/no unknown
- 2000-11-28 IS IS5737A patent/IS5737A/is unknown
- 2000-12-08 ZA ZA200007300A patent/ZA200007300B/en unknown
- 2000-12-18 BG BG105060A patent/BG65021B1/bg unknown
2001
- 2001-09-11 HK HK01106420A patent/HK1035726A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA002988B1 (ru)	2002-12-26
EE200000698A (et)	2002-06-17
KR100636713B1 (ko)	2006-10-20
BG105060A (en)	2001-08-31
CZ298413B6 (cs)	2007-09-26
NO317990B1 (no)	2005-01-17
HUP0102255A2 (hu)	2001-11-28
IL139967A (en)	2005-11-20
EA200001236A1 (ru)	2001-06-25
ZA200007300B (en)	2002-02-27
IS5737A (is)	2000-11-28
ES2211096T3 (es)	2004-07-01
WO1999061421A1 (en)	1999-12-02
PT1082302E (pt)	2004-04-30
UA65623C2 (en)	2004-04-15
AU764108B2 (en)	2003-08-07
NZ509199A (en)	2003-10-31
KR20010043906A (ko)	2001-05-25
JP2002516309A (ja)	2002-06-04
TR200100190T2 (tr)	2001-05-21
ATE256659T1 (de)	2004-01-15
HK1035726A1 (en)	2001-12-07
DK1082302T3 (da)	2004-04-26
MXPA00011774A (es)	2002-10-17
PL344440A1 (en)	2001-11-05
EP1082302B1 (en)	2003-12-17
AU4219299A (en)	1999-12-13
HUP0102255A3 (en)	2001-12-28
CZ20004425A3 (en)	2001-05-16
DE69913687T2 (de)	2004-10-07
CA2333656C (en)	2008-07-29
YU75500A (sh)	2002-12-10
EE04639B1 (et)	2006-06-15
SK285280B6 (sk)	2006-10-05
US6495525B1 (en)	2002-12-17
CN1307561A (zh)	2001-08-08
NO20006023D0 (no)	2000-11-28
SK18102000A3 (sk)	2001-07-10
BG65021B1 (bg)	2006-12-29
CA2333656A1 (en)	1999-12-02
IL139967A0 (en)	2002-02-10
DE69913687D1 (de)	2004-01-29
SI1082302T1 (en)	2004-06-30
CN1148350C (zh)	2004-05-05
EP1082302A1 (en)	2001-03-14
PL198189B1 (pl)	2008-06-30

Publication	Publication Date	Title
NO20006023L (no)	2001-01-17	Celleadhesjonsinhibitor samt farmasöytiske sammensetninger inneholdende denne
BR9908280A (pt)	2000-10-31	Inibidores de enzimas de fosfolipase
PT966465E (pt)	2003-11-28	Inibidores do enzima imfdh
WO2003024899A3 (en)	2003-11-27	CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
NO307340B1 (no)	2000-03-20	Krystallinsk hydroklorid av (R)-(-)-2-{N-[4-(1,1-dioksido-3- okso-2,3-dihydro-benzisotiazol-2-yl)-butyl]-aminometyl}-kroman, legemiddel inneholdende samme, samt fremstilling og anvendelse av samme
WO2000069896A3 (en)	2001-07-05	Molecular interactions in haematopoietic cells
AU2002218311A1 (en)	2002-06-11	Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
WO2001090138A3 (en)	2002-03-21	SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
CA2047744A1 (en)	1990-08-22	Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
EA200400708A1 (ru)	2004-10-28	Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
AU2924699A (en)	1999-08-23	Tryptase inhibitors
WO2004093788A3 (en)	2005-06-30	Desmoglein 4 is a novel gene involved in hair growth
PT830130E (pt)	2004-11-30	Enzima de conversao de tnf-alfa
HUP0202729A2 (hu)	2003-01-28	Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
AU2003271811A1 (en)	2004-02-02	Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
NO980296L (no)	1998-01-23	Forbedrede terapeutiske midler
AU2001261519A1 (en)	2001-11-26	Methods of affecting laminin 5 processing
ES2172182T3 (es)	2002-09-16	Composiciones farmaceuticas que comprenden cefuroxima axetil.
WO2001016355A3 (de)	2001-08-30	In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
ZA200104508B (en)	2002-09-02	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors.
EA200400709A1 (ru)	2004-12-30	Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
DE60015559D1 (de)	2004-12-09	Sentrin-spezifische menschliche protease senp1
FR2654430B1 (fr)	1995-01-06	Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.
AU2001238115A1 (en)	2001-08-20	Novel amino acid and peptide inhibitors of staphylococcus virulence
WO2005056770A3 (en)	2005-11-24	Band 5: a human testis specific protein